Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study.

Ugurluer, Gamze; Miller, Robert C; Li, Yexiong; Thariat, Juliette; Ghadjar, Pirus; Schick, Ulrike; Ozsahin, Mahmut (2016). Primary Hepatic Lymphoma: A Retrospective, Multicenter Rare Cancer Network Study. Rare tumors, 8(3), pp. 118-123. PAGEPress 10.4081/rt.2016.6502

[img]
Preview
Text
Primary hepatic lymphoma.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (581kB) | Preview

Primary hepatic lymphoma (PHL) is a rare malignancy. We aimed to assess the clinical profile, outcome and prognostic factors in PHL through the Rare Cancer Network (RCN). A retrospective analysis of 41 patients was performed. Median age was 62 years (range, 23-86 years) with a male-to-female ratio of 1.9:1.0. Abdominal pain or discomfort was the most common presenting symptom. Regarding B-symptoms, 19.5% of patients had fever, 17.1% weight loss, and 9.8% night sweats. The most common radiological presentation was multiple lesions. Liver function tests were elevated in 56.1% of patients. The most common histopathological diagnosis was diffuse large B-cell lymphoma (65.9%). Most of the patients received Chop-like (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimens; 4 patients received radiotherapy (dose range, 30.6-40.0 Gy). Median survival was 163 months, and 5- and 10-year overall survival rates were 77 and 59%, respectively. The 5- and 10-year disease-free and lymphoma-specific survival rates were 69, 56, 87 and 70%, respectively. Multivariate analysis revealed that fever, weight loss, and normal hemoglobin level were the independent factors influencing the outcome. In this retrospective multicenter RCN study, patients with PHL had a relatively better prognosis than that reported elsewhere. Multicenter prospective studies are still warranted to establish treatment guidelines, outcome, and prognostic factors.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Ghadjar, Pirus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2036-3605

Publisher:

PAGEPress

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

16 Mar 2017 09:35

Last Modified:

13 Sep 2017 20:35

Publisher DOI:

10.4081/rt.2016.6502

PubMed ID:

27746888

Uncontrolled Keywords:

Non-Hodgkin’s lymphoma; chemotherapy; primary hepatic lymphoma

BORIS DOI:

10.7892/boris.92695

URI:

https://boris.unibe.ch/id/eprint/92695

Actions (login required)

Edit item Edit item
Provide Feedback